findmyKOL

Louis Philipson

Basic profile

Endocrinology, Diabetes & Metabolism

ORCIDNone on fileNPI
RegionChicago, IL · MidwestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationNot yet indexedOnline presenceNot yet checkedPayments2021 onwardNIH funding1992–2026Why? →

Louis Philipson is an Endocrinology/Metabolic physician.

Overview

Scholarship

indexed output and impact (OpenAlex)

Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →

Clinical & industry

trials, payments and federal funding
4companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
10NIH grants · 1992–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

5841 S Maryland Ave
Chicago, IL 606371443

Telephone

888-824-0200

Registry record last updated 24 Oct 2022.

View the NPPES registry record

Industry payments

4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    79.5%
    Insulin Analog42.6%
    Humalog18%Lantus Solostar17%Novolog Flexpen14%Humalog Kwikpen U-1009%Novolog9%Basaglar Kwikpen U-1008%Insulin Lispro8%Fiasp Flextouch6%Humalog Kwikpen U-2006%Tresiba Flextouch U-1005%
    Part D<11 patients
    GLP-1 receptor agonist18.6%
    Mounjaro74%Ozempic26%
    Part D<11 patients

    + 3 more classes in this area

  • Cardiovascular

    13.6%
    Statin7.2%
    Rosuvastatin Calcium55%Atorvastatin Calcium45%
    Part D<11 patients
    Angiotensin receptor blocker (ARB)6.4%
    Candesartan Cilexetil65%Losartan Potassium35%
    Part D<11 patients
  • Hormonal (systemic)

    7%
    l-Thyroxine7%
    Levothyroxine Sodium100%
    Part D12 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

10 NIH research awards on record, funded 19922026 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”